Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit

Lushun Yuan, Shuzhen Cheng, Wendy M.P.J. Sol, Anouk I.M. van der Velden, Hans Vink, Ton J. Rabelink, Bernard M. van den Berg in collaboration with the BEAT-COVID study group
ERJ Open Research 2022 8: 00652-2021; DOI: 10.1183/23120541.00652-2021
Lushun Yuan
1The Einthoven Laboratory for Vascular and Regenerative Medicine, Dept of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuzhen Cheng
2Dept of Internal Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy M.P.J. Sol
1The Einthoven Laboratory for Vascular and Regenerative Medicine, Dept of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anouk I.M. van der Velden
1The Einthoven Laboratory for Vascular and Regenerative Medicine, Dept of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Vink
3Dept of Physiology, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
4MicroVascular Health Solutions LLC, Alpine, UT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ton J. Rabelink
1The Einthoven Laboratory for Vascular and Regenerative Medicine, Dept of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard M. van den Berg
1The Einthoven Laboratory for Vascular and Regenerative Medicine, Dept of Internal Medicine, Nephrology, Leiden University Medical Center, Leiden, The Netherlands
5For a list of the BEAT-COVID study group members and their affiliations see the Acknowledgements
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bernard M. van den Berg
  • For correspondence: bmvandenberg@lumc.nl
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Figures

  • Supplementary Materials
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Comparison and association of endothelial dysfunction and glycocalyx shedding related markers in coronavirus disease 2019 (COVID-19) patients and healthy controls. Levels of a) angiopoietin 2 (ANG2), b) soluble thrombomodulin (sTM) and c) soluble syndecan-1 (sSDC1) between healthy controls (n=12), COVID-19 non-intensive care unit (ICU) patients (n=8), COVID-19 ICU patients (n=26) and recovered patients (n=18). Pearson's correlation between d) ANG2 and sTM, e) ANG2 and sSDC1, f) sTM and sSDC1. Graphs represent mean±sd. One-way ANOVA followed by Tukey's multiple comparisons test and Pearson's correlation analysis were performed. *: p<0.05; **: p<0.01; ***: p<0.001.

  • FIGURE 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2

    Loss of glycocalyx in primary human pulmonary microvascular endothelial cells in the presence of serum of coronavirus disease 2019 (COVID-19) patients in the intensive care unit (ICU). a) Representative fluorescence (FL) confocal images of Lycopersicon esculentum (LEA)-fluorescein isothiocyanate (FITC) or anti-thrombomodulin (TM) staining on the surface of primary human pulmonary microvascular endothelial cells (HPMECs) in the presence of 10% serum of pooled healthy controls (n=12), COVID-19 non-ICU (n=8) and COVID-19 ICU (n=26) samples for 24 h. HPMEC surface expression quantification of b) LEA-FITC and c) TM in the presence of 10% pooled healthy control, COVID-19 non-ICU and COVID-19 ICU serum for 24 h. All values are given as mean±sd of four independent experiments. One-way ANOVA followed by Tukey's multiple comparisons test was performed. ***: p<0.001.

  • FIGURE 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3

    Serum mediators of coronavirus disease 2019 (COVID-19) patients in the intensive care unit (ICU) induce microvascular barrier disruption. Barrier integrity parameter, resistance of a and b) primary human pulmonary microvascular endothelial cells (HPMECs) and c and d) primary human glomerular microvascular endothelial cells (GEnCs) assessed by electric cell-substrate impedance sensing system (ECIS Zθ) in response to stimulation with 10% serum (at t=0 h) of healthy controls (n=12), COVID-19 non-ICU (n=8) and COVID-19 ICU (n=26). Cell–cell contact parameter, Rb of e and f) HPMECs and g and h) GEnCs assessed by ECIS Zθ in response to stimulation with 10% serum (at t=0 h) of healthy controls (n=12), COVID-19 non-ICU (n=8) and COVID-19 ICU (n=26). In some cases, multiple samples (in ICU and out of ICU) from the same patient at different time points were obtained. Data of raw resistance and Rb values were shown and presented as mean±sem. Quantification of barrier integrity was based on the measurements of area under the curve (AUC) over the final 15 h of b) HPMECs and d) GEnCs. Quantification of cell–cell contact was based on the measurements of AUC over the final 15 h of f) HPMECs and h) GEnCs. i) Representative confocal images of VE-cadherin (green) and F-actin (red) staining on HPMECs in the presence of 10% pooled healthy control (n=12), COVID-19 non-ICU (n=8) and COVID-19 ICU (n=26) serum for 24 h (scale bar=20 µm). j) Quantification of adhesion junction percentage of HPMECs in the presence of 10% pooled healthy control, COVID-19 non-ICU and COVID-19 ICU serum for 24 h of four independent experiments. Graphs represent the mean±sd. k) Pearson's correlation heatmap between endothelial dysfunction and glycocalyx shedding-related markers (angiopoietin 2 (ANG2), soluble thrombomodulin (sTM) and soluble syndecan-1 (sSDC1)) and barrier function-related parameters (last 15 h AUC of R and Rb in HPMECs and GEnCs). Colours represent correlation, blue means negative correlation and red means positive correlation. Blank means no significance. One-way ANOVA followed by Tukey's multiple comparisons test and Kruskal–Wallis test followed by Dunn's multiple comparisons test were performed. *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.

  • FIGURE 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4

    Fucoidan restores glycocalyx thickness on human pulmonary microvascular endothelial cells (HPMECs) and reduces endothelial activation. a) Representative confocal images of Lycopersicon esculentum (LEA)-fluorescein isothiocyanate (FITC) or anti-thrombomodulin (TM) staining on the surface of primary HPMECs in the presence of 10% pooled coronavirus disease 2019 (COVID-19) intensive care unit (ICU) (n=26) serum with and without fucoidan (10 µg mL−1) for 24 h. Quantification of HPMECs surface b) LEA and c) TM expression in the presence of 10% pooled COVID-19 ICU serum with and without fucoidan (10 µg mL−1) for 24 h of four independent experiments. d) Western blot images of intercellular adhesion molecule (ICAM)1, p-P65, t-P65 protein expression. Quantification of e) ICAM1/GAPDH ratio and f) p-P65/t-P65 ratio in HPMECs in response to 10% pooled healthy control (n=12), COVID-19 non-ICU (n=8) and COVID-19 ICU (n=26) serum with and without fucoidan (10 µg mL−1) for 24 h of four independent experiments, presented as fold change expression normalised to healthy control. Secreted g) von Willebrand factor (VWF), h) angiopoietin 2, i) interleukin-6 (IL-6) and (j) soluble thrombomodulin (sTM) of HPMECs stimulated with 10% individual COVID-19 ICU sera (n=26) with and without fucoidan (10 µg·mL−1) for 24 h. FL: fluorescence. One-way ANOVA followed by Tukey's multiple comparisons test, Kruskal–Wallis test followed by Dunn's multiple comparisons test and paired two-tailed t-test were performed. **: p<0.01; ***: p<0.001; ****: p<0.0001.

  • FIGURE 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5

    Fucoidan could ameliorate endothelial cell barrier function in presence of serum of coronavirus disease 2019 (COVID-19) intensive care unit (ICU) patients. a) Barrier integrity parameter, resistance of primary human pulmonary microvascular endothelial cells (HPMECs) assessed by electric cell-substrate impedance sensing system (ECIS) in response to stimulation with 10% serum (at t=0 h) of healthy controls (n=12, grey line), COVID-19 ICU (n=26, red line) and COVID-19 ICU with fucoidan (n=26, blue line). Cell–cell contact parameter, Rb of c) HPMECs assessed by ECIS in response to stimulation with 10% serum (at t=0 h) of healthy controls (n=12, grey line), COVID-19 ICU (n=26, red line) and COVID-19 ICU with fucoidan (n=26, blue line). Data were normalised to the baseline resistance or Rb to calculate the relative resistance or Rb to baseline (%) and presented as mean±sem. b) Quantification of barrier integrity was based on the measurements of area under the curve (AUC) of final 15 h. d) Quantification of cell–cell contact was based on the measurements of AUC of final 15 h. e) Representative confocal images of VE-cadherin (green) and F-actin (red) staining on HPMECs in the presence of 10% pooled COVID-19 ICU serum with and without fucoidan (10 µg mL−1) for 24 h (scale bar=20 µm). f) Quantification of adhesion junction percentage of HPMECs in the presence of 10% pooled COVID-19 ICU serum with and without fucoidan (10 µg mL−1) for 24 h of four independent experiments. Graphs represent the mean±sd. Nonpaired and paired two-tailed t-test were performed. ****: p<0.0001.

  • FIGURE 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6

    Fucoidan inhibits the formation of procoagulant cell surface in response to serum of coronavirus disease 2019 (COVID-19) intensive care unit (ICU) patients. a) Schematic overview showing how to detect FX activation on primary human pulmonary microvascular endothelial cell (HPMEC) surface in response to 10% healthy control or COVID-19 serum. FXa production (nM) in b) first hour and c) second hour on HPMECs surface in the presence of 10% individual COVID-19 ICU sera (n=26) with and without fucoidan (10 µg mL−1) for 24 h. d) Schematic overview showing how to detect thrombin generation on HPMECs cell surface in response to 10% healthy control or COVID-19 serum. e) Representative graph of thrombin generation assay in the presence of 10% healthy control, COVID-19 non-ICU, and COVID-19 ICU with and without fucoidan (same serum induced cell surface). f) Thrombin generation peak height (nM) measured on HPMECs surface in the presence of 10% individual COVID-19 ICU serum (n=26) with and without fucoidan (10 µg mL−1) for 24 h. g) Pearson's correlation heatmap between endothelial dysfunction and glycocalyx shedding-related markers (angiopoietin-2 (ANG2), soluble thrombomodulin (sTM) and soluble syndecan-1 (sSDC1)) and coagulation assay parameters (FXa 1 h, FXa 2 h and thrombin peak height). Colours represent correlation; blue means negative correlated and red means positive correlated. Blank means no significance. Graphs represent the mean±sd and paired two-tailed t-tests were performed. *: p<0.05; ****: p<0.0001.

Supplementary Materials

  • Figures
  • Supplementary Material

    Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

    Supplementary material 00652-2021.SUPPLEMENT

    Graphical abstract 00652-2021.GRAPHICAL_ABSTRACT

PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
ERJ Open Research: 8 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit
Lushun Yuan, Shuzhen Cheng, Wendy M.P.J. Sol, Anouk I.M. van der Velden, Hans Vink, Ton J. Rabelink, Bernard M. van den Berg
ERJ Open Research Apr 2022, 8 (2) 00652-2021; DOI: 10.1183/23120541.00652-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Heparan sulfate mimetic fucoidan restores the endothelial glycocalyx and protects against dysfunction induced by serum of COVID-19 patients in the intensive care unit
Lushun Yuan, Shuzhen Cheng, Wendy M.P.J. Sol, Anouk I.M. van der Velden, Hans Vink, Ton J. Rabelink, Bernard M. van den Berg
ERJ Open Research Apr 2022, 8 (2) 00652-2021; DOI: 10.1183/23120541.00652-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Material and methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Research Articles

  • Longitudinal passive cough monitoring
  • Severe PH-CLD and loss of small pulmonary vessels on CT
  • Effect of the COVID-19 pandemic on severe asthma care
Show more Original Research Articles

COVID-19

  • Longitudinal passive cough monitoring
  • Severe PH-CLD and loss of small pulmonary vessels on CT
  • Effect of the COVID-19 pandemic on severe asthma care
Show more COVID-19

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2022 by the European Respiratory Society